Rituximab efficacy in caps

dc.contributor.author	Yakymenko, O.	en
dc.contributor.author	Vasylets, V.	en
dc.contributor.author	Klochko, V.	en
dc.contributor.author	Savytskyi, V.	en
dc.contributor.author	Tikhonchuk, N.	en
dc.date.accessioned	2020-12-16T06:37:25Z
dc.date.available	2020-12-16T06:37:25Z
dc.date.issued	2020
dc.identifier.citation	Rituximab efficacy in caps / O. Yakymenko, V. Vasylets, V. Klochko, V. Savytskyi, N. Tikhonchuk // Lupus Science & Medicine. 2020. N 7. P. 31–32.	en
dc.identifier.uri	https://repo.odmu.edu.ua:443/xmlui/handle/123456789/8432
dc.description.abstract	Catastrophic antiphospholipid syndrome (CAPS) – thrombotic microvasculopathy, characterized by involvement of systems and organs with formation of their insufficiency. Therapy of glucocorticoids and immunosuppressants with plasmapheresis and intravenous immunoglobulin demonstrates lack of effectivity. Currently, there are reports of rituximab effectiveness in APS and CAPS, but they are not numerous, especially CAPS. Methods Assessment of the rituximab effectiveness in patients with resistant CAPS. We present the treatment results of two patients with CAPS, who were treated in our clinic.	en
dc.language.iso	en	en
dc.subject	rituximab	en
dc.subject	сatastrophic antiphospholipid syndrome	en
dc.subject	thrombotic microvasculopathy	en
dc.subject	therapy of glucocorticoids and immunosuppressants	en
dc.title	Rituximab efficacy in caps	en
dc.type	Article	en